- 3.3% of the women who used RU-486 in the first trimester of pregnancy reported to an emergency room compared with 2.2% who used a surgical method;
- 5.7% (1 in 18 patients) of the women who used RU-486 had to be re-admitted to hospitals compared with 0.4%
- (1 in 250) of surgical abortion patients. With respect to second-trimester RU-486 abortions:
- A staggering 33% (16/49) required some form of surgical intervention;
- 4% had “significant haemorrhage;” one of the two patients in this category required a transfusion.
Walker also noted in The Australian, “Two of the 5,823 surgical patients suffered severe haemorrhage, involving the loss of more than a litre of blood.” That approximated “a rate of one in 3000.” Walker observed as well “[f]our of the 947 women who had medical abortions had the same problem, lifting the rate to one in 200.” These statistics pertain to first trimester abortions.
In summary, the Australian study underscores the fact also seen in the Finnish data—RU-486 requires a substantial follow-up and support system to minimize dangers associated with its use. The backup capacity should include ultrasound, transfusion ability, and emergent surgical capability to follow-up an incomplete abortion.
United States of America
FDA’s April 2011 RU-486 Adverse Events Summary states that “[t]he estimated number of women who have used mifepristone in the US through the end of April 2011 is approximately 1.52 million women.” As noted above, FDA calculated that by that date there had been 2,207 adverse event reports submitted to FDA.
Hospitalization, Excluding Deaths
There were 612 reports of hospitalization received as of April 30, 2011.
339 women “experienced blood loss requiring a transfusion” after taking the RU-486 abortion regimen.
There were 256 baseline infections cases defined as: [including] endometritis (involving the lining of the womb), pelvic inflammatory disease (involving the nearby reproductive organs such as the fallopian tubes or ovaries), and pelvic infections with sepsis (a serious systemic infection that has spread beyond the reproductive organs…
There were also 48 reports of severe infections which were described as a subset of infections including: Severe infections generally involve death or hospitalization for at least 2-3 days, intravenous antibiotics for at least 24 hours, total antibiotic usage for at least 3 days, and any other physical or clinical findings, laboratory data or surgery that suggest a severe infection.
- FDA states that eight of fourteen fatalities it had tracked were associated with sepsis
- 7 cases tested positive for Clostridium sordellii, 1 case tested positive for Clostridium perfringens.” All but one fatal sepsis case reported vaginal misoprostol use; buccal misoprostol use was reported in one case